In summary, in HCC patients resistant to prior anti-PD-(L)1 treatments, rechallenge with dual immunotherapy comprising anti-PD-1 and anti-CTLA-4 has shown some evidence of antitumor efficacy. The gene discussed is CD274; the disease is hepatocellular carcinoma.